MX2020012979A - Métodos para aumentar la exposición al plasma de sepiapterina. - Google Patents

Métodos para aumentar la exposición al plasma de sepiapterina.

Info

Publication number
MX2020012979A
MX2020012979A MX2020012979A MX2020012979A MX2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A
Authority
MX
Mexico
Prior art keywords
sepiapterin
methods
plasma exposure
increasing plasma
csf
Prior art date
Application number
MX2020012979A
Other languages
English (en)
Spanish (es)
Inventor
Neil Smith
Jonathan Reis
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2020012979A publication Critical patent/MX2020012979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2020012979A 2018-05-30 2019-05-30 Métodos para aumentar la exposición al plasma de sepiapterina. MX2020012979A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US201962822376P 2019-03-22 2019-03-22
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Publications (1)

Publication Number Publication Date
MX2020012979A true MX2020012979A (es) 2021-04-29

Family

ID=68699037

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012979A MX2020012979A (es) 2018-05-30 2019-05-30 Métodos para aumentar la exposición al plasma de sepiapterina.
MX2024005935A MX2024005935A (es) 2018-05-30 2020-11-30 Metodos para aumentar la exposicion al plasma de sepiapterina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005935A MX2024005935A (es) 2018-05-30 2020-11-30 Metodos para aumentar la exposicion al plasma de sepiapterina.

Country Status (20)

Country Link
US (3) US11617752B2 (https=)
EP (2) EP4454704A3 (https=)
JP (2) JP7502197B2 (https=)
CN (1) CN112703002A (https=)
AU (2) AU2019277382B2 (https=)
CA (1) CA3102106A1 (https=)
DK (1) DK3801536T3 (https=)
ES (1) ES2986920T3 (https=)
FI (1) FI3801536T3 (https=)
HR (1) HRP20241213T1 (https=)
HU (1) HUE068589T2 (https=)
LT (1) LT3801536T (https=)
MD (1) MD3801536T2 (https=)
MX (2) MX2020012979A (https=)
PL (1) PL3801536T3 (https=)
PT (1) PT3801536T (https=)
RS (1) RS65874B1 (https=)
SI (1) SI3801536T1 (https=)
SM (1) SMT202400430T1 (https=)
WO (1) WO2019232130A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
EP4093405A1 (en) * 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
WO2022173823A1 (en) * 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
EP2562176B1 (en) * 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN104736539B (zh) 2012-05-07 2017-09-01 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法
EP3213062B1 (en) * 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
WO2019102315A1 (en) * 2017-11-23 2019-05-31 Semiconductor Energy Laboratory Co., Ltd. Display device and electronic device
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Also Published As

Publication number Publication date
EP3801536A4 (en) 2022-03-23
CA3102106A1 (en) 2019-12-05
SI3801536T1 (sl) 2024-12-31
DK3801536T3 (da) 2024-08-19
LT3801536T (lt) 2024-09-25
JP2024069192A (ja) 2024-05-21
ES2986920T3 (es) 2024-11-13
PL3801536T3 (pl) 2025-02-03
FI3801536T3 (fi) 2024-08-29
US11617752B2 (en) 2023-04-04
EP4454704A3 (en) 2025-01-01
US20230381181A1 (en) 2023-11-30
US12329757B2 (en) 2025-06-17
MD3801536T2 (ro) 2024-11-30
JP2021525729A (ja) 2021-09-27
AU2019277382A1 (en) 2021-01-21
CN112703002A (zh) 2021-04-23
HRP20241213T1 (hr) 2024-11-22
WO2019232130A1 (en) 2019-12-05
AU2019277382B2 (en) 2025-01-09
SMT202400430T1 (it) 2024-11-15
HUE068589T2 (hu) 2025-01-28
PT3801536T (pt) 2024-09-19
JP7841005B2 (ja) 2026-04-06
US20260091037A1 (en) 2026-04-02
EP3801536B1 (en) 2024-07-17
RS65874B1 (sr) 2024-09-30
AU2025200814A1 (en) 2025-02-27
EP3801536A1 (en) 2021-04-14
US20210220363A1 (en) 2021-07-22
EP4454704A2 (en) 2024-10-30
MX2024005935A (es) 2024-06-04
JP7502197B2 (ja) 2024-06-18

Similar Documents

Publication Publication Date Title
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
AR132544A2 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
MX2019012445A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
UY35962A (es) Formulaciones de liberación modificada de pridopidina
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
CL2021000930A1 (es) Piridazinas novedosas
MX374705B (es) Composiciones que comprenden anakinra.
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
UY36331A (es) Composición farmacéutica sólida que comprende amlodipina y losartán